Prostate cancer originates in the male prostate gland and has become one of the most common types of cancer. It typically remains confined in this region, however it may spread to other locations throughout the body. Risk of prostate cancer increases with age, family history, obesity, and ethnicity as black males are the most likely to develop prostate cancer. Treatment for prostate cancer includes radiation therapy, hormone therapy, surgery, and chemotherapy. Hormone refractory prostate cancer occurs when various hormone therapies fail to prevent the development of the prostate cancer. This failure can occur for various amounts of time, ranging from months or years after therapy has began. Occasionally, stopping the androgen blockade and introducing testosterone into the blood stream may help with preventing tumor growth. However, fear of hormone refractory prostate cancer is the cancer will spread, thus the next step typically includes chemotherapy drugs.
Hormone Refractory Prostate Cancer Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Hormone Refractory Prostate Cancer below!
For more information on how to use Laverne, please read the How to Guide.
We have 2151 products for the study of Hormone Refractory Prostate Cancer that can be applied to Western Blot, Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry from our catalog of antibodies and ELISA kits.